

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10088129	
	Filing Date		2002-03-14	
	First Named Inventor	David Norman Wells		
	Art Unit	1632		
	Examiner Name	Ton, Thuan N.		
Attorney Docket Number		36697.6		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	9946962		1999-09-23	Bresagen Limited	

If you wish to add additional U.S. Patent citation information please click the Add button. [Add](#)

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button. [Add](#)

FOREIGN PATENT DOCUMENTS								Remove
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	Ts
	1	9946962	WO		1999-09-23	Bresagen Limited		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button. [Add](#)

NON-PATENT LITERATURE DOCUMENTS			Remove
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	Ts

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10088129
Filing Date		2002-03-14
First Named Inventor	David Norman Wells	
Art Unit	1632	
Examiner Name	Ton, Thaian N.	
Attorney Docket Number	36697.6	

1	Barnes et al., "Influence of Recipient Oocyte Cell Cycle Stage on DNA Synthesis, Nuclear Envelope Breakdown, Chromosome Constitution and Development in Nuclear Transplant Bovine Embryos," Mol. Reprod. Dev., 36:33-41, 1993.	<input type="checkbox"/>
2	Boquest et al., "Flow Cytometric Cell Cycle Analysis of Cultured Porcine Fetal Fibroblast Cells," Biol. Reprod., 60:1013-1019, 1999.	<input type="checkbox"/>
3	Campbell et al., "Cell Cycle Co-ordination in Embryo Cloning by Nuclear Transfer," Reviews Reprod, 1:40-46, 1996.	<input type="checkbox"/>
4	Campbell et al., "Sheep Cloned by Nuclear Transfer From a Cultured Cull Line," Nature, 380:64-66, 1996.	<input type="checkbox"/>
5	Campbell et al., "Production of Live Lambs Following Nuclear Transfer of Cultured Embryonic Disc Cells," Theriogenology, 43:153-365, Abstract No. 181, 1995.	<input type="checkbox"/>
6	Campbell et al., "Improved Development to Blastocyst of Ovine Nuclear Transfer Embryos Reconstructed During the Presumptive S-phase of Enucleated Activated Oocytes," Biol. Reprod, 50:1385-1393, 1994.	<input type="checkbox"/>
7	Campbell et al., "Nuclear-Cytoplasmic Interactions During the First Cell Cycle of Nuclear Transfer Reconstructed Bovine Embryos: Implications for Deoxyribonucleic Acid Replication and Development," Biol. Reprod., 49:933-942, 1993.	<input type="checkbox"/>
8	Cibelli et al., "Cloned Transgenic Calves Produced From Nonquiescent Fetal Fibroblasts," Science, 280:1256-1258, 1998.	<input type="checkbox"/>
9	Collas et al., "Influence of Cell Cycle Stage of the Donor Nucleus on Development of Nuclear Transplant Rabbit Embryos," Biol. Reprod, 46:492-500, 1992a.	<input type="checkbox"/>
10	Collas et al., "Effect of Donor Cell Cycle Stage on Chromatin and Spindle Morphology in Nuclear Transplant Rabbit Embryos," Biol. Reprod, 46:501-511, 1992b.	<input type="checkbox"/>
11	Czolowska et al., "Behaviour of Thymocyte Nuclei in Non-Activated and Activated Mouse Oocytes," J. Cell Sci., 69:19-34, 1984.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10088129
Filing Date	2002-03-14
First Named Inventor	David Norman Wells
Art Unit	1632
Examiner Name	Ton, Thaian N.
Attorney Docket Number	36697.6

12	Gadbois et al., "Multiple Kinase Arrest Points in the G1 Phase of Nontransformed Mammalian Cells are Absent in Transformed Cells," Proc. Natl. Acad. Sci., USA, 89:8626-8630, 1992.	<input type="checkbox"/>
13	Gardner et al., "Enhanced Rates of Cleavage and Development for Sheep Zygotes Cultured to the Blastocyst Stage h" Vitro in the Absence of Serum and Somatic Cells: Amino Acids, Vitamins and Culturing Embryos in Groups Stimulate Development, Biol. Reprod 50:390-400, 1994.	<input type="checkbox"/>
14	Otaegui et al., "Transfer of Nuclei From 8-Cell Stage Mouse Embryos Following Use of Nocodazole to Control the Cell Cycle," Mol. Reprod Dev., 39:147-52, 1994.	<input type="checkbox"/>
15	Pedersen, "Embryonic Stem Cells for Medicine," Scientific American, April 1999:44-49.	<input type="checkbox"/>
16	Perry et al., "Mammalian Transgenesis by Intracytoplasmic Sperm Injection," Science, 284:1180-1183, 1999.	<input type="checkbox"/>
17	Pinto-Correia et al., "Factors Involved in Nuclear Reprogramming During Early Development in the Rabbit", Mol. Reprod. Dev, 40:292-304, 1995.	<input type="checkbox"/>
18	Schnieke et al., "Human Factor IX Transgenic Sheep Produced by Transfer of Nuclei From Transfected Fetal Fibroblasts," Science, 278:2130-2133, 1997.	<input type="checkbox"/>
19	Sherwood et al., "Defining Cellular Senescence in 1MR-90 cells: A Flow Cytometric Analysis," Proc. Natl. Acad. Sci., USA, 85:9086-9090, 1988.	<input type="checkbox"/>
20	Stice et al. "Pluripotent Bovine Embryonic Cell Lines Direct Embryonic Development Following Nuclear Transfer," Biol. Reprod, 54:100-110, 1996.	<input type="checkbox"/>
21	Susko-Parrish et al. "Inhibition of Protein Kinases Aider an Induced Calcium Transient Causes Transition of Bovine Oocytes to Embryonic Cycles Without Meiotic Completion," Develop. Biol., 166:729-739, 1994.	<input type="checkbox"/>
22	Tada et al., "Embryonic Germ Cells Induce Epigenetic Reprogramming of Somatic Nucleus in Hybrid Cells," EMBO,Z, 16:6510-6520, 1997.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10088129
Filing Date	2002-03-14
First Named Inventor	David Norman Wells
Art Unit	1632
Examiner Name	Ton, Thaian N.
Attorney Docket Number	36697.6

23	Thomson et al., "Embryonic Stem Cell Lines Derived From Human Blastocysts," Science, 282:1145-1147, 1998.	<input type="checkbox"/>
24	Thompson et al., "Effect of Oxygen Concentration on In Vitro Development of Preimplantation Sheep and Cattle Embryos," J. Reprod. Fertility, 89:573-578, 1990.	<input type="checkbox"/>
25	Vignon et al., "Development of Bovine Nuclear Transfer Embryos Reconstituted With Quiescent and Proliferative Skin Fibroblasts," Theriogenology, 51:161-438; Abstract No. 216, 1999.	<input type="checkbox"/>
26	Vignon et al., "Developmental Potential of Bovine Embryos Reconstructed From Enucleated Matured Oocytes Fused With Cultured Somatic Cells," C R Academy of Science, Paris 321: 735-745, 1998.	<input type="checkbox"/>
27	Wakayama et al., "Mice Cloned From Embryonic Stem Cells," Proc. Natl. Acad. Sci. USA, 96(26):14984-89, 1999a.	<input type="checkbox"/>
28	Wakayama and Yanagimachi, "Cloning of Male Mice From Adult Tail-Tip Cells," Nature Genetics, 22:127-128, 1999b.	<input type="checkbox"/>
29	Wall et al., "Transgenic Dairy Cattle: Genetic Engineering on a Large Scale," J. Dairy Science, 80:2213-2224, 1997.	<input type="checkbox"/>
30	Wells et al., "Adult Somatic Cell Nuclear Transfer is Used to Preserve the Last Surviving Cow of the Enderby Island Cattle Breed," Reprod. Fertility Develop., 10:369-378, 1999.	<input type="checkbox"/>
31	Wells et al., "Production of Cloned Bovine Fetuses Following Nuclear Transfer With Cells From a Fetal Fibroblast Cell Line," Theriogenology, 49:153-404; Abstract No. 330, 199	<input type="checkbox"/>
32	Wilmut et al., "Viable Offspring Derived From Fetal and Adult Mammalian Cells," Nature, 385:810-813, 1997.	<input type="checkbox"/>
33	Zakhartchenko et al., "Effects of Serum Starvation and Re-Cloning on the Efficiency of Nuclear Transfer Using Bovine Fetal Fibroblasts," J. Reprod. Fertility, 115:325-331, 1999.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10088129
Filing Date	2002-03-14
First Named Inventor	David Norman Wells
Art Unit	1632
Examiner Name	Ton, Thaian N.
Attorney Docket Number	36697.6

34	International Search Report for PCT Application PCT/AU99/00165, mailed April 16, 1999	<input type="checkbox"/>
----	---	--------------------------

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10088129
Filing Date	2002-03-14
First Named Inventor	David Norman Wells
Art Unit	1632
Examiner Name	Ton, Thaian N.
Attorney Docket Number	36697.6

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- ☐ See attached certification statement.
- ☒ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ☐ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Mark D. Moore/	Date (YYYY-MM-DD)	2006-10-13
Name/Print	Mark D. Moore, Ph.D.	Registration Number	42,903

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.